I’m sorry
Sangamo Treatments (Nasdaq:SGMO(It lost nearly half of its market value in early trading on Tuesday after Pfizer)New York Stock Exchange:PFE) decided to end cooperation with the company regarding the gene therapy giroctocogene fitelparvovec, which targets bleeding. Hemophilia A disorder.
sangamo (
https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2075111295/image_2075111295.jpg?io=getty-c-w750
Source link